Mental Health

Beyond the fireworks and festivities, Canada Day 2026 reveals a sophisticated strategy of public-private partnership and multi-platform engagement.

A new survey reveals a major disconnect between American values on volunteerism and corporate action, posing a hidden risk to talent retention and ESG ratings.

A new grand jury report exposes a perfect storm in SF jails: surging inmates with severe health needs, crumbling buildings, and burned-out staff.

Dana-Farber's historic $50M Yawkey grant funds more than a building; it fuels a new era of integrated research and patient-centric cancer treatment.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

A $95K grant fuels an innovative Chicago partnership integrating community doulas into hospitals, aiming to reverse the deadly trend of Black maternal mortality.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

One PR agency's new certification as a woman-owned business reveals a powerful economic ecosystem designed to foster inclusive growth and corporate responsibility.

Isabelle Fortier's appointment to the CCSA board brings frontline Arctic experience to national policy, a crucial move in Canada's evolving fight against the overdose crisis.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

A charity shooting match raised $30,000, but the real story is how corporate-community partnerships are forging a new model for veteran mental health.

A deadly, vaccine-less Ebola strain is spreading in Central Africa. As governments scramble, the CDC Foundation deploys its most potent weapon: agile funding.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

A new generation of men is shattering the stigma around mental health at work, but a startling retention gap reveals a deeper crisis for employers.

New research shows 'Food is Medicine' programs thrive when paired with human coaching, offering a potent, scalable model for tackling chronic disease.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.